Trial Profile
A Phase II, safety, tolerability and efficacy study of topical AKP-11 administration to participants with atopic dermatitis.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Jul 2019
Price :
$35
*
At a glance
- Drugs AKP 11 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Akaal Pharma
- 14 Jan 2019 Status changed from recruiting to discontinued.
- 13 Jul 2017 Status changed from not yet recruiting to recruiting.
- 25 Aug 2016 New trial record